Exploring the effectiveness of hesperidin and narirutin in treating prostate cancer and benign prostatic hyperplasia, suggesting new drug development avenues.
Anti-proliferative assays, network pharmacology, and molecular docking collectively demonstrate that hesperidin and narirutin from CR show strong therapeutic potential against PCa and BPH. The findings highlight the involvement of AGE-RAGE and p53 signalling pathways and support the potential of these compounds in future drug development.
No takes yet. Share an insight, caveat, or question.
Hsieh et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: